This study is testing a new way to prevent Graft Versus Host Disease (GVHD) after a stem cell transplant. GVHD is a complication where the new immune cells attack the patient's body. Researchers are combining two existing treatments: post-transplant cyclophosphamide (PTCY) and a mix of urinary-derived human chorionic gonadotropin and epidermal growth factor (uhCG/EGF). The main goal is to see if this combination is safe and feasible. You might be able to join if you are 18-70 years old, have a blood cancer requiring a stem cell transplant, and meet certain health requirements for your kidneys and liver. The study is also looking at how well it prevents GVHD and improves survival. The current recruitment status is unclear.

Study design

This is a Phase 1 interventional study with a planned enrollment of 18 participants. It is designed to evaluate the safety and feasibility of the treatment combination.

What's involved

You would receive PTCY for two doses after your stem cell transplant, followed by uhCG/EGF injections under the skin on days 7, 9, and 11 after your transplant. Safety will be measured up to 30 days after the stem cell transplant.

Compensation

Not stated in the trial record.

Follow-up

The primary endpoints for safety and dose-limiting toxicity are measured at day +30 post stem cell transplant.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.